www.fdanews.com/articles/177582-coherus-neulasta-biosimilar-succeeds-in-phase-3-study
Coherus’ Neulasta Biosimilar Succeeds in Phase 3 Study
July 18, 2016
Coherus BioSciences has released positive results from a pharmacokinetic and pharmacodynamic study assessing its biosimilar candidate CHS-1701.
In the biosimilarity study comparing CHS-1701 to Amgen’s Neulasta, the candidate reached all of its co-primary endpoints.
Overall, there were no adverse events related to the treatment.